Executive Medical Director
Regeneron Pharmaceuticals, Inc
Tarrytown, New York
Glenn S. Kroog, MD is the Clinical Program Lead at Regeneron Pharmaceuticals for linvoseltamab, a BCMAxCD3 bispecific antibody recently approved in the United States and Europe for relapsed/refractory multiple myeloma. In his academic career, Dr. Kroog studied G protein-coupled receptor signal transduction at the National Institutes of Health and Albert Einstein College of Medicine, and treated patients with kidney cancer and other genitourinary tract cancers at Memorial Sloan-Kettering Cancer Center. Since moving to the pharmaceutical industry, Dr. Kroog has participated in the development of many drugs including elotuzumab and dasatinib for hematologic malignancies and checkpoint inhibitors and bispecific antibodies for solid tumors.
Disclosure information not submitted.
Saturday, September 20, 2025
10:41 - 10:49 East Coast USA Time